ArticleWorld journal of gastrointestinal pharmacology and therapeutics2012
Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Ten-day concomitant and sequential therapy for Helicobacter pylori effective in region with high antibiotic resistance rates.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022Trial
- Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.World journal of gastroenterology · 2015Trial
- Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.European journal of clinical pharmacology · 2013Trial
- Investigating the link betweenAnnals of medicine and surgery (2012) · 2026Article
- Efficacy of Vonoprazan for Helicobacter pylori Eradication.Internal medicine (Tokyo, Japan) · 2020Review
- A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-lineInfection and drug resistance · 2019Article
- Gastric cancer diagnosed after Helicobacter pylori eradication in diabetes mellitus patients.BMC gastroenterology · 2015Article
- Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Molecules (Basel, Switzerland) · 2015Review
- Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection.Current treatment options in gastroenterology · 2014Article
- Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.World journal of gastroenterology · 2014Review
- Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.United European gastroenterology journal · 2014Article
- Helicobacter pylori: management in 2013.World journal of gastroenterology · 2014Review
- Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients?World journal of gastrointestinal pharmacology and therapeutics · 2012Article
- High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment ofTzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo find the way to improve the eradication rate of first-line therapy in Japanese patients.
methodsWe prospectively compared the effectiveness of 7-d quadruple therapy to standard 7 d triple therapy in Japanese patients infected with Helicobacter pylori (H. pylori). One hundred and nineteen patients were randomly assigned to receive 7-d non-bismuth quadruple therapy with lansoprazole, amoxicillin, clarithromycin and metronidazole (LACM7) or 7-d triple therapy with lansoprazole, amoxicillin and clarithromycin (LAC7). After three months, H. pylori status was analyzed by (13)C-urea breath test. Incidence rates of adverse events were evaluated by use of questionnaires.
resultsBy intention-to-treat (ITT) analysis, the eradication rate in the LACM7 group was 94.9%, which was significantly higher than the LAC7 group (68.3%, P < 0.001). Per protocol analysis also showed a significantly higher eradication rate in the LACM7 group (98.3%) than the LAC7 group (73.2%, P < 0.001). Nevertheless, the incidence of serious adverse events did not differ between the two groups (RR: 1.10, 95% CI: 0.70-1.73, P = 0.67).
conclusionSeven day non-bismuth quadruple therapy (LACM7) was superior to standard 7-d triple therapy (LAC7) for first-line eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.